Literature DB >> 1384010

Possible existence of a new tachykinin receptor subtype in the guinea pig ileum.

F Petitet1, M Saffroy, Y Torrens, S Lavielle, G Chassaing, D Loeuillet, J Glowinski, J C Beaujouan.   

Abstract

The guinea pig ileum possesses NK-1 and NK-3 tachykinin receptors. As expected, [Pro9]SP and senktide, which are selective agonists of NK-1 and NK-3 receptors, respectively, were found to be highly potent in contracting the guinea pig ileum. Surprisingly, similar observations were made with septide, SP-O-CH3, [Apa9-10]SP, or [Pro9,10]SP although, in contrast to [Pro9]SP, these four peptides showed a low affinity for 3H-[Pro9]SP-specific NK-1 binding sites on membranes from the guinea pig ileum. They were also devoid of affinity for NK-2 and NK-3 binding sites. GR 71251, a compound which has been described as a NK-1 antagonist, was more potent in inhibiting the septide- than the [Pro9]SP-evoked contracting response. Altogether, these results suggest that septide, [Apa9-10]SP, and [Pro9,10]SP exert their high contracting activity in the guinea pig ileum by acting on a new subtype of tachykinin receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384010     DOI: 10.1016/0196-9781(92)90125-m

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  23 in total

1.  Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.

Authors:  S B Mazzone; D P Geraghty
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 2.  Innervation of the synovium.

Authors:  P I Mapp
Journal:  Ann Rheum Dis       Date:  1995-05       Impact factor: 19.103

3.  Evidence that tachykinins relax the guinea-pig trachea via nitric oxide release and by stimulation of a septide-insensitive NK1 receptor.

Authors:  M Figini; C Emanueli; C Bertrand; P Javdan; P Geppetti
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.

Authors:  Francesca Bellucci; Francesca Carini; Claudio Catalani; Paola Cucchi; Alessandro Lecci; Stefania Meini; Riccardo Patacchini; Laura Quartara; Renzo Ricci; Manuela Tramontana; Sandro Giuliani; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor: evidence from quantitation of receptor endocytosis.

Authors:  K M Jenkinson; B R Southwell; J B Furness
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists.

Authors:  J C Beaujouan; E Heuillet; F Petitet; M Saffroy; Y Torrens; J Glowinski
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

7.  Tachykinin NK1 and NK2 receptor antagonists and atropine-resistant ascending excitatory reflex to the circular muscle of the guinea-pig ileum.

Authors:  C A Maggi; R Patacchini; L Bartho; P Holzer; P Santicioli
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Role of neurokinin 1 receptors in dextran sulfate-induced colitis: studies with gene-deleted mice and the selective receptor antagonist netupitant.

Authors:  István Szitter; Erika Pintér; Anikó Perkecz; Agnes Kemény; József Kun; László Kereskai; Claudio Pietra; John P Quinn; Andreas Zimmer; Alexandra Berger; Christopher J Paige; Zsuzsanna Helyes
Journal:  Inflamm Res       Date:  2014-01-28       Impact factor: 4.575

9.  Synergistic role of muscarinic acetylcholine and tachykinin NK-2 receptors in intestinal peristalsis.

Authors:  P Holzer; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

10.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

Authors:  O Piot; J Betschart; I Grall; S Ravard; C Garret; J C Blanchard
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.